Regencell Bioscience (RGC) has had the highest return since January 1, 2025 by a US stock in the Biotechnology Industry, returning 18,313.2%.
| ASSET | % RETURN |
|---|---|
Regencell Bioscience (RGC) | 18,313.17% |
Abivax SA American Depositary Shares (ABVX) | 1,907.04% |
Palvella Therapeutics (PVLA) | 811.54% |
Cidara Therapeutics (CDTX) | 714.68% |
Celcuity LLC (CELC) | 676.17% |
Nanobiotix (NBTX) | 628.3% |
Anbio Biotechnology Class A Ordinary Shares (NNNN) | 581.37% |
Galecto (GLTO) | 516.95% |
Invivyd (IVVD) | 497.87% |
DBV Technologies (DBVT) | 478.42% |
NovaBridge Biosciences (NBP) | 444.71% |
I-Mab (IMAB) | 444.71% |
Inhibrx Biosciences (INBX) | 424.89% |
GRAIL, LLC (GRAL) | 415.49% |
Cogent Biosciences (COGT) | 402.91% |
Olema Pharmaceuticals (OLMA) | 363.68% |
CytomX Therapeutics (CTMX) | 335.64% |
ABVC BioPharma (ABVC) | 294.92% |
Gossamer Bio (GOSS) | 276.37% |
AnaptysBio (ANAB) | 272.65% |
Arrowhead Pharmaceuticals (ARWR) | 270.17% |
Nuvation Bio (NUVB) | 255.22% |
Praxis Precision Medicines (PRAX) | 253.53% |
CervoMed (CRVO) | 253.33% |
Precigen (PGEN) | 249.17% |
